Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2026 16:05 ET | Source: Abivax

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax to Present Data on Obefazimod at Digestive Disease Week® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical...
April 22, 2026 16:05 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia

Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22, 2026 ...
April 22, 2026 16:05 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026

BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines BBO-11818...
April 22, 2026 09:30 ET | Source: LIfT BioSciences

LIfT BioSciences Announces Publication of Review Article in Frontiers in Immunology Highlighting Broad Therapeutic Potential of Neutrophils and IMANs in Cancer

Neutrophils, long considered short-lived immune cells, can be therapeutically targeted when their appropriate subset and functional state are identified for the disease contextLIfT BioSciences’...
April 22, 2026 09:00 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman

Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development...
April 22, 2026 09:00 ET | Source: Capricor Therapeutics

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today...
April 22, 2026 08:30 ET | Source: BioMedWire

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is...
April 22, 2026 08:30 ET | Source: CytoDyn Inc.

CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026

Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, supporting CCR5 as a...
April 22, 2026 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
April 22, 2026 08:00 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701

NORWOOD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today...